| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 29, 2019- Results from Independent Imaging Review of patients with hepatocellular carcinoma receiving lenvatinib+pembrolizumab in KEYNOTE-524 / Study 116 after five additional months of follow-up will be presented
Eisai announces today that one mini-symposium and 15 poster presentations from its oncology pipeline will be highlighted at the American Association for Cancer Research (AACR) 110th Annual Meeting...
-
Mar 6, 2019
Eisai announced today that new data from a real world observational study of the use of eribulin mesylate injection (marketed as HALAVEN®) following cyclin-dependent kinase (CDK) 4/6 inhibitor in...
-
Feb 11, 2019
Presenting sponsor Eisai Inc. and METAvivor announce today that they have joined forces with AnaOno Intimates and Project #Cancerland to bring to life the #ThisIsMBC Elements campaign through...
-
Jan 14, 2019
Eisai Inc. announced today the presentation of four abstracts at the 2019 Gastrointestinal Cancers Symposium (#GI19), taking place in San Francisco from January 17-19, 2019. The presentations...
-
Nov 28, 2018Project Unveils Powerful Portraits of People Living with Metastatic Breast Cancer and Their Caregivers Overcoming Real-Life Struggles to Inspire Others
Eisai Inc. and METAvivor today announced the launch of Elements, a new initiative of the #ThisIsMBC campaign. Elements spotlights nine people living with metastatic breast cancer (MBC) and their...
